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Trends in the epidemiology of human brucellosis in 
Germany were investigated by analyzing national sur-
veillance data (1962–2005) complemented by a ques-
tionnaire-based survey (1995–2000). After a steady de-
crease in brucellosis incidence from 1962 to the 1980s, 
a persistent number of cases has been reported in recent 
years, with the highest incidence in Turkish immigrants 
(0.3/100,000 Turks vs. 0.01/100,000 in the German popu-
lation; incidence rate ratio 29). Among cases with reported 
exposure risks, 59% were related to the consumption of 
unpasteurized cheese from brucellosis-endemic countries. 
The mean diagnostic delay was 2.5 months. Case fatal-
ity rates increased from 0.4% (1978–1981) to a maximum 
of 6.5% (1998–2001). The epidemiology of brucellosis in 
Germany has evolved from an endemic occupational dis-
ease among the German population into a travel-associ-
ated foodborne zoonosis, primarily affecting Turkish immi-
grants. Prolonged diagnostic delays and high case fatality 
call for targeted public health measures.
Brucellosis is one of the most common zoonotic dis-
eases worldwide (1). The disease is caused by Brucella spp. 
and is transmitted from its animal reservoirs to humans by 
direct contact with infected animals or, more often, through 
the consumption of raw animal products such as unpasteur-
ized milk or cheese. Four of 6 nomen species of the ge-
nus Brucella are pathogenic for humans, i.e., B. melitensis 
(transmitted from sheep and goats), B. abortus (from cattle 
and other bovidae), B. suis (from pigs), and B. canis (from 
dogs) (2).
In Germany, human brucellosis was highly endemic 
from the 1950s well into the 1980s, with up to 500 cases re-
ported annually. Most of these cases were related to occu-
pational exposure associated with calf breeding and dairy 
farming, leading to a predominance of B. abortus infec-
tions (3,4). Because of successfully established eradication 
and control programs for animal brucellosis, the number 
of human cases decreased steadily. In 2000, Germany was 
declared “ofﬁ   cially free from ovine/caprine and bovine 
brucellosis” (5). Human brucellosis cases, however, con-
tinued to occur in Germany. Although limited case series 
from Germany and Denmark indicate that human brucello-
sis could be associated with travel to and immigration from 
disease-endemic areas (6,7), there are no population-based 
or nationwide studies on epidemiologic characteristics of 
the disease in northern and central Europe.
The objective of our study was to describe trends in 
laboratory-conﬁ  rmed human brucellosis in Germany over 
the past 40 years by analyzing national surveillance data. 
To provide background information, which may be useful 
for targeting public health measures, we focused on geo-
graphic origin and source of infection, modes of transmis-
sion, risk factors, and regional distribution of the disease.
Methods
In the former German Democratic Republic (East Ger-
many), human brucellosis became a reportable disease in 
1951. From 1947 through 1961, in the former Federal Re-
public of Germany (West Germany) only B. abortus infec-
tions were reported. After 1962, brucellosis (independent 
of the disease-causing species) became a reportable disease 
according to the West German Federal Communicable Dis-
ease Act, which was the applicable law after the reuniﬁ  ca-
tion in 1990.
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Detailed data about brucellosis patients were compiled 
from 1995 through 2005 on demographics (age, sex, na-
tionality, and current residence), onset of symptoms, clini-
cal signs (fever, night sweats, fatigue, lack of appetite or 
weight loss, headache, arthralgia), contact dates with the 
treating physician, hospitalization, death, laboratory diag-
nosis, bacterial species, geographic origin, and possible 
vehicle of infection. The data collected from 1995 through 
2000 are based on a standardized questionnaire, which was 
sent to local health departments for every reported case of 
brucellosis (8). Since 2001, similar information has been 
available from an improved surveillance system imple-
mented for mandatory case reporting of infectious diseas-
es. Fatal brucellosis cases documented on death certiﬁ  cates 
(1962–2005) were obtained from the Information System 
of Federal Health Monitoring, Germany (www.gbe-bund.
de); population data were provided by the Federal Statisti-
cal Ofﬁ  ce, Germany (www.destatis.de).
Both clinical signs (the occurrence of an acute febrile 
illness or 2 other clinical signs) and laboratory conﬁ  rma-
tion (positive culture, only 1 signiﬁ  cant titer, or an increase 
in the titer in the follow-up serum sample) were required 
to meet  the case deﬁ  nition for brucellosis (9). From 1995–
2005, isolates suspected to be Brucella spp. were sent from 
various microbiologic laboratories throughout Germany to 
the former German Reference Center for Human Brucel-
losis at the Federal Institute for Risk Assessment in Ber-
lin. Standard microbiologic methods were used for further 
identiﬁ  cation (10).
To assess temporal trends, mean annual incidences 
and case-fatality ratios were calculated for 4-year intervals 
starting from 1962 through 2005. Statistical tests for trend 
were performed by using the Cochrane-Armitage test (11); 
95% conﬁ  dence intervals were calculated according to Wil-
son (12). The Mann-Whitney test was used for comparative 
analysis of continuous variables. We tested for signiﬁ  cance 
of incidence rate ratios (IRRs) using a Poisson regression 
model. Odds ratios (ORs) were tested for signiﬁ  cance by us-
ing the χ2 test. Data were analyzed with EpiInfo version 6.04 
(Centers for Disease Control and Prevention, Atlanta, GA, 
USA) and Stata version 9.0 (StatCorp., College Station, TX, 
USA). A p value <0.05 was considered signiﬁ  cant.
Results
From 1962–2005, 6,269 human brucellosis cases were 
reported in Germany. During this 44-year period, the an-
nual number of cases generally declined (Figure 1). The 
mean annual incidence decreased from 0.6/100,000 pop-
ulation (1962–1965) to the lowest observed incidence of 
0.03/100,000 population during 1998–2001 (Figure 2). 
A total of 58 deaths were caused by brucellosis (overall 
case-fatality rate 0.9%). The lowest case-fatality rate was 
0.4% in 1978–1981. From then on, a signiﬁ  cantly increas-
ing trend (p<0.01) reaching a maximum of 6.5% in 1998–
2001 was observed, which subsequently dropped to 2.1% 
in 2002–2005.
Through 1974, most of the brucellosis cases were re-
ported from East Germany, with a maximum of 82% in 
1969. After 1974, the relative number of cases reported in 
East Germany decreased compared with those in West Ger-
many. Since 1981, brucellosis has been rarely reported in 
East Germany; the West-East divide was still present after 
reuniﬁ  cation (Figure 3).
From 1995 to 2005, a total of 290 brucellosis cases 
were reported, of which 245 (84%) met  the case deﬁ  ni-
tion and were included in this analysis. Area of residence, 
sex, age, clinical symptoms, and laboratory ﬁ  ndings were 
known for all 245 case-patients. Most cases were report-
ed in the federal states of North Rhine Westphalia (49), 
Baden-Württemberg (45), Bavaria (39), and Hesse (23); in 
the cities of Berlin (19), Hamburg (8) and Bremen (4); and 
in large conurbations, e.g. Munich (10) and Ludwigshafen 
(8). The spatial distribution of brucellosis cases was associ-
ated with the immigrant density in the administrative dis-
tricts (Figure 3).
Both sexes were almost equally represented among 
brucellosis patients (54% male vs. 46% female). In patients 
<30 years of age and >59 years of age, male sex predomi-
nated (60% and 73%, respectively); in persons 30–59 years 
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Figure 1. Reported brucellosis cases, Germany, 1962–2005.
Figure 2. Incidence (per 100,000 inhabitants) and case-fatality 
rate for brucellosis, Germany, 1962–2005. Error bars indicate 95% 
conﬁ  dence intervals.Epidemiology of Human Brucellosis, Germany
of age, 56% were female. The age-speciﬁ  c incidence was 
highest for persons 60–69 years of age, with a mean annual 
incidence of 0.05/100,000, and lowest for children <10 
years of age, with a mean annual incidence of 0.02/100,000 
(Figure 4).
Detailed data about the nationality of patients were 
available for 106 (43%) of the 245 cases. A total of 58 
(55%) were non-Germans, of which 62% (36) were Turk-
ish. Four were Italian, 3 each were Greek and Iraqi, 2 were 
Kazakh, and 1 each were Bosnian, Kosovar, Portuguese, 
Syrian, Arabian, Indian, Pakistani, Yemeni, and Somali; 
in 1 case, a non-German status was reported without na-
tionality. The incidence rate was 0.3/100,000 in Turks and 
0.01/100,000 in Germans (IRR 29, p<0.01).
The country where the infection had been contracted 
was known for 234 (96%) of 245 cases. In 172 cases (74%), 
the origin of infection was likely to be outside Germany. Of 
these, 137 (80%) were associated with travel to disease-
endemic countries surrounding the Mediterranean Sea, e.g. 
Turkey (94), Italy (13), and Spain (9). Possible origins of 
infection were the Balkans for 5 cases, African countries 
for 7 cases, Middle Eastern countries (not bordering the 
Mediterranean Sea) for 6 cases, Minor Asian countries for 
9 cases, former Soviet Union countries for 5 cases, and 
the Czech Republic for 1 case. Two patients were infected 
overseas (Peru and New Zealand). In 62 cases (26%), the 
origin of infection was assumed to be Germany.
In 102 (42%) of 245 patients, >1 probable source of 
infection could be identiﬁ  ed. Fifty-six (55%) had only 1 
exposure risk, whereas the other 46 patients (45%) men-
tioned various combinations. Twenty-seven patients con-
sumed unpasteurized milk, 65 patients ate unpasteurized 
cheese or other dairy products, and 7 patients ate raw meat. 
Foodborne infections were almost equally distributed 
among Turks and Germans (31% vs. 35%). Direct contact 
with cattle, sheep and goats was reported by 16, 24, and 
16 patients, respectively. Most of the people infected by 
direct animal contact were Turks (49%); only 29% were 
Germans.
In 18 cases (18%), a possible occupational exposure 
was reported. Among these, 7 infections were laboratory-
acquired, exclusively in German cases. The other work-re-
lated cases were linked to direct contact with animals or 
animal products outside Germany. Two shepherds, 2 per-
sons working on a sheep breeding farm, 2 farmers, 4 butch-
ers and 1 veterinarian were affected. In 84 cases (82%), no 
occupational exposure risk was observed.
Ten minor outbreaks were reported during 1995–2005. 
Four cases were epidemiologically linked to Brucella infec-
tions observed in friends and relatives living in disease-en-
demic countries, i.e., Turkey, Italy, and Bosnia. In 7 cases, 
the patient was related to at least 1 other person living in 
Germany who also had Brucella infection. One laboratory-
acquired infection and its index case were also reported as 
an outbreak.
The date of onset for symptomatic disease was report-
ed for 207 (84%) of 245 cases. In most cases, the onset 
of disease was in August or September (31%). Another 
smaller peak comprising 23 cases (11%) occurred in June 
(Figure 5). In 85 cases, more detailed information about the 
incubation period was available. The period between pre-
sumed infection and onset of symptomatic disease varied 
extremely, ranging from a few days to 24 months (median 
4 weeks).
The major symptom in 215 (88%) of 245 patients was 
fever, which was signiﬁ  cantly associated with hospitaliza-
tion of the patient (OR 4.1; p<0.01). A total of 121 (49%) 
patients reported fatigue; 105 (43%) reported arthralgia, 
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Figure 3. Regional distribution of brucellosis cases and percentage 
of immigrants per county, Germany, 1995–2005.
Figure 4. Age and sex distribution of brucellosis cases (n = 245), 
Germany, 1995–2005.RESEARCH
101 (41%) reported headaches, 66 (27%) reported massive 
sweating, 30 (12%) reported loss of appetite, and 31 (13%) 
reported loss of weight.
The delay between onset of disease and deﬁ  nite labo-
ratory-conﬁ  rmed diagnosis was reported for 175 cases. The 
mean diagnostic delay was 2.5 months, with no differences 
between ethnic groups. In 77 patients (44%), brucellosis 
was diagnosed within 4 weeks. For 89 patients (51%), di-
agnostic delay ranged from 1 to 6 months. In the remaining 
9 patients (5%), brucellosis was deﬁ  nitely diagnosed >6 
months after onset of symptoms.
In 24 cases, the period between the ﬁ  rst presumptive 
diagnosis and the ﬁ  nal laboratory conﬁ  rmation was report-
ed; the mean period was 6 days. Sixty-three (26%) patients 
were treated as outpatients, while 181 (74%) were hospital-
ized. In 1 case, this information was not available.
From 1995–2005, a total of 134 cases was culture-
proven at the former German Reference Centre for Human 
Brucellosis at the Federal Institute for Risk Assessment 
in Berlin. Standard microbiologic tests identiﬁ  ed 131 B. 
melitensis isolates (98%), 1 B. suis strain, and 2 B. abortus 
strains. Of the 245 total cases, 164 (67%) were diagnosed 
by serologic tests, 113 (69%) by serum agglutination test 
(SAT), 3 (2%) by complement ﬁ  xation (CFT), and 15 (9%) 
by ELISA. In 31 cases (19%), a positive SAT was con-
ﬁ  rmed by CFT or ELISA. In 2 cases, the serologic tests 
used could not be identiﬁ  ed. Among the cases with sero-
logic conﬁ  rmation (n = 164), 1 strongly elevated titer was 
reported for 81 patients, while seroconversion was shown 
in 11 patients. In 72 cases, no data on the type of serologic 
conﬁ  rmation was available.
Discussion
Up to the mid-1980s, a substantial decrease in the in-
cidence of human brucellosis was observed in Germany. 
However, national surveillance data demonstrated a persis-
tent level of reported cases in recent years. Our study indi-
cates that these infections are primarily related to persons 
with a migrational background. Taking into account that 
<10% of Brucella infections are recognized and reported 
because of unspeciﬁ  c clinical symptoms (13,14), our results 
strongly suggest that human brucellosis has emerged as an 
important and probably neglected health problem among 
immigrants in Germany. The present epidemiology of bru-
cellosis in Germany mirrors the reemergence of the disease 
in Turkey. An increase in brucellosis incidence has also 
been reported from several other countries in the Middle 
East and the Balkans (1), which emphasizes the magnitude 
of the problem and its potential to accelerate in the future. 
Immigrants from these regions form an increasing propor-
tion of the German population.
The current status of brucellosis in Germany is the re-
sult of continuous changes in the epidemiologic character-
istics of the disease during the past 40 years. The number 
of reported autochthonous human cases continuously de-
creased in parallel to the decreasing prevalence of infected 
animals. At the same time, the number of immigrants, espe-
cially from Turkey, increased considerably. In 1960, only 
1% of the German population was foreign born and only 
2,700 Turkish residents lived in Germany. In 2004, ≈8.8% 
of the population was foreign born, and Turks formed the 
largest foreign nationality group, with 1,764,318 immi-
grants (24% of all foreigners).
Our results indicate that the exposure risk of Turkish 
immigrants to Brucella spp. continues after immigration to 
Germany, with a brucellosis incidence (0.3 cases/100,000 
Turkish immigrants) falling between the incidence in 
the German population as a whole (0.01 cases/100,000 
Germans) and the incidence observed in Turkey (26.2 
cases/100,000 population) (1). The continuing risk may 
be attributed to more frequent exposures during summer 
recreational activities in disease-endemic countries, e.g., 
when visiting friends and relatives in rural areas. In brucel-
losis-endemic regions, the peak for human brucellosis is in 
June and July (15–17). Onset of disease occurs in August 
and September, just after the end of the German summer 
holiday season, in most reported cases. In addition, Bru-
cella spp. may survive for several days up to months in 
contaminated food products privately imported from dis-
ease-endemic countries (18), which may contribute to in-
fections contracted in Germany. An association of brucel-
losis with the immigrant population has previously been 
reported from Denmark and the United States (7,19). In the 
United States, Hispanic ethnicity, recent travel to disease-
endemic areas in Mexico, and ingestion of nonpasteurized 
dairy products are major risk factors for Brucella infections 
(13,19–22).
Brucellosis was traditionally more prevalent in Ger-
man states with a high degree of agricultural activity. Our 
results demonstrate a fundamental shift of brucellosis from 
a rural disease into an infection of urban and suburban resi-
dents. Because most immigrants live in the centers of in-
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Figure 5. Seasonal distribution of brucellosis cases (n = 207), 
Germany, 1995–2005.Epidemiology of Human Brucellosis, Germany
dustry, most cases were reported from cities and areas with 
high-density populations in Germany. The pronounced 
West-East divide we observed mirrors the much higher 
proportion of foreign-born people in western Germany 
compared with eastern Germany (10.1% versus 2.4%).
Regarding the age distribution in our study group, only 
16% of the reported cases were <20 years of age. The age-
speciﬁ  c incidence was highest in persons 60–69 years of 
age. These persons were mainly ﬁ  rst-generation immigrants 
who keep in closer contact with family members still living 
in their homelands. A similar age-speciﬁ  c incidence distri-
bution has been described in studies from other countries 
not endemic for brucellosis, whereas in brucellosis-endem-
ic countries, cases of this disease do not cluster in a particu-
lar age class (16). We did not observe a male predominance 
in the working age group as in countries where brucellosis 
is strongly related to occupational exposure risks. In Ger-
many, brucellosis has evolved into a foodborne disease, 
and unpasteurized goat cheese is the most frequently re-
ported vehicle of exposure in our study population; thus, 
there is no reason to expect gender predominance. From 
1995–2005, 2.9% of the cases reported were associated 
with Brucella infections in family members. The serologic 
screening of household members of brucellosis patients 
may therefore help to detect these frequently unrecognized 
cases with identical risk factors (23).
In Germany, ≈7% of the infections with a known source 
were laboratory acquired. Brucella spp. are among the most 
commonly recognized causes of laboratory-transmitted in-
fections worldwide, but only 2% of all human cases are 
actually laboratory-acquired (13,24). This discrepancy may 
reﬂ  ect that microbiologists in German laboratories are not 
aware of brucellosis as a possible case of fever of unknown 
origin because the disease is very rare in Germany. A low 
index of suspicion and misidentiﬁ  cation of the organism 
may lead to a higher proportion of laboratory-associated 
infections.
Consistent with the literature, fever >38.5°C was the 
leading symptom in most (88%) of our patients. Osteoartic-
ular manifestations are known to be the most frequent focal 
complications (17,25,26) and were reported in 43% of our 
cases. Key results of our study are the extensive diagnostic 
delay in brucellosis and the exceptionally high case-fatal-
ity rate. The degree of illness in patients with fever of un-
known origin is directly related to the diagnostic delay. In 
56% of the cases reported in Germany, symptoms lasted >4 
weeks before diagnosis, and the mean diagnostic delay was 
2.5 months. It is well documented that the number of fo-
cal complications increases with a diagnostic delay of >30 
days and the risk for an unfavorable clinical course is much 
higher in patients with focal complications (25). In disease-
endemic areas, the index of suspicion is high, and the dura-
tion of symptomatic disease before hospital admission is 
<2 weeks in 72% of the cases (27). In part, the increase in 
deaths observed in our study may be caused by a lack of 
suspicion by medical professionals. In addition, language 
barriers may hinder obtaining detailed medical histories 
from immigrants (28).
Most human brucellosis cases worldwide are caused 
by B. melitensis (29), which is also true in Germany (98% 
of all isolates). Most B. melitensis strains isolated in Ger-
many are of the East-Mediterranean genotype (30), which 
is consistent with the epidemiologic data presented.
Conclusions
In Germany, brucellosis has emerged as a disease 
among Turkish immigrants. In this population group, the 
infection is associated with major diagnostic delays, possi-
bly resulting in treatment failures, relapses, chronic courses, 
focal complications, and a high case-fatality rate. Because 
of a lack of knowledge on the changing epidemiology of 
the disease, many physicians may not be able to act efﬁ  -
ciently as ﬁ  rst responders recognizing natural or artiﬁ  cial 
outbreaks. Public health programs should therefore focus 
on educating the Turkish segment of the German popula-
tion about the risks of consuming animal products imported 
from Turkey or unpasteurized cheese and other dairy prod-
ucts during visits to Turkey. In addition, healthcare provid-
ers should be informed about the disease, especially if they 
work in areas with a large Turkish population.
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